Description

COMPOSITION:

Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg

INDICATION: 

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

LuciTram is indicated, in combination with dabrafenib, for:

· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.

· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

DOSAGE AND USE:

The recommended dosage of LuciTram is 2 mg orally once daily. Take LuciTram at least 1 hour before or at least 2 hours after a meal.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 2°C to 8°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciTram in Pregnancy and Lactation patient treatment.